Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | LTA4H | P09960 | 5/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | BAX | Q07812 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594405 | 0.84 | AHR (0.50) | KEAP1AHRPDPK1NPC1TNK2 | |
| SCHEMBL5661955 | 0.78 | GSTP1 (0.48) | GSTP1KEAP1AHRPDPK1NPC1 | |
| SCHEMBL24034931 | 0.76 | AHR (0.46) | KEAP1AHRPDPK1BRD4 | |
| SCHEMBL27487511 | 0.76 | AHR (0.46) | KEAP1AHRPDPK1RIPK1 | |
| SCHEMBL6089266 | 0.76 | AHR (0.46) | KEAP1AHRPDPK1RIPK1TNK2 | |
| SCHEMBL4718619 | 0.76 | KEAP1 (0.49) | KEAP1LTA4HAHRPDPK1TSHR | |
| SCHEMBL7088348 | 0.75 | NPC1 (0.49) | KEAP1AHRPDPK1NPC1BRD4 | |
| SCHEMBL7088143 | 0.74 | PIK3CD (0.57) | GSTP1SCN9ALTA4HAHR | |
| SCHEMBL31492457 | 0.74 | AHR (0.60) | KEAP1AHRPDPK1BRD4 | |
| 4-Phenoxyaniline SCHEMBL10656295 | 0.73 | MAOA (0.51) | KEAP1AHRPDPK1TSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202344-B2 | Aryl substituted indoles and the use thereof | PURDUE PHARMA L.P. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2582666-B1 | ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS | PURDUE PHARMA LP (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20030203959-A1 | Novel modulators of potassium channels | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203959-A1 | Novel modulators of potassium channels | HCN3, KCNN3, KCNN1 | GSTP1 3282/4885SCN9A 90/4885KEAP1 1445/4885 |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | SCN5A, TRPV1, TRPV5 | GSTP1 974/4885SCN9A 75/4885KEAP1 1676/4885 |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | GSTP1 558/4885SCN9A 110/4885KEAP1 1425/4885 |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | GSTP1 558/4885SCN9A 110/4885KEAP1 1425/4885 |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | TRPC5, TRPV5, TRPV1 | GSTP1 558/4885SCN9A 110/4885KEAP1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.